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Abstract
Purpose The aims of the study were to develop a population
pharmacokinetic model of orally administered brivaracetam in
paediatric patients and to provide dosing suggestions.
Methods Analysis included 600 brivaracetam plasma concentra-
tions from a phase 2a study (NCT00422422; N01263) in 96
paediatric patients with epilepsy aged 1month to 16 years, taking
one to three concomitant antiepileptic drugs (AEDs).
Pharmacokinetic analysis was performed using non-linear mixed
effects modelling, and a stepwise covariate search was used to
determine factors influencing brivaracetam clearance.
Simulations were performed to investigate dosing regimens.
Results The final model consisted of first-order absorption, sin-
gle compartment distribution and first-order elimination compo-
nents with allometric scaling of clearance and volume using lean
body weight and fixed allometric exponents. Co-administration
with phenobarbital or carbamazepine was associated with a 29%
(95%CI 17%/39%) and 32% (22%/42%) decrease in exposure,
respectively. Co-administration with valproate was associated
with an 11% (1%/23%) increase in exposure. Simulations dem-
onstrated that the majority of children were predicted to have an
exposure similar to that in adults, using an age-independent
dosing regimen of 2.0 mg/kg bid with a maximum of 100 mg
bid for body weight >50 kg.
Conclusions A paediatric dose adaptation of 2.0 mg/kg twice
daily with a maximum of 100 mg twice daily for body weight
>50 kg is predicted to ensure steady-state plasma concentra-
tions in the same range as in adult patients receiving 100 mg
twice daily (highest recommended dose). Data suggest no
need to change brivaracetam dosing when used concomitantly
with carbamazepine, phenobarbital or valproate.
Keywords Brivaracetam . Paediatrics . Epilepsy . Population
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Introduction
Seventy million people have epilepsy with 34–76 per 100,000
developing the condition every year [1]. The incidence varies
greatly with age, with high rates occurring in childhood, fall-
ing to low levels in early adult life, but with a second peak in
those aged over 65 years. Epilepsy affects about 4 to 6 out of
1000 children below the age of 20 years, and the overall an-
nual incidence rates of epilepsy for all seizure types range
between 45 and 86 out of 100,000 children. Despite the avail-
ability of new antiepileptic drugs (AEDs), more than 25% of
paediatric patients have inadequate seizure control on current-
ly available AEDs, or experience significant adverse drug ef-
fects [2]. There remains a need for potent AEDs with a posi-
tive benefit-risk profile in this population.
Brivaracetam is a selective, high-affinity synaptic vesicle pro-
tein 2A ligand [3] that was recently approved as adjunctive ther-
apy in the treatment of focal (partial onset) seizures in patients
16 years of age and older with epilepsy [4–8]. Brivaracetam is
rapidly and highly absorbed and peak plasma concentrations are
generally reached within 2 h after dosing in fasting subjects
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[9, 10]. The disposition of brivaracetam is characterised by linear
pharmacokinetics over a large range of doses (10 to 600 mg).
Brivaracetam is eliminated primarily by metabolism, which is
partially cytochrome P450 dependent. The three main metabo-
lites are not pharmacologically active. Only a small fraction (up
to 10%) of the dose is excreted as parent compound in the urine
[11]. Brivaracetam is available as bioequivalent tablets, oral so-
lution and intravenous injection [12, 13].
We report the results of non-linear mixed effects modelling of
brivaracetam pharmacokinetics from a phase 2a trial in paediatric
epilepsy patients (NCT00422422; N01263 [14]), including a co-
variate analysis and determination of paediatric dosing
adaptations.
Methods
Trial N01263 was conducted in accordance with the
International Conference on Harmonization notes for
Guidance on Good Clinical Practice and the Declaration of
Helsinki. The study protocol was approved by institutional
review boards at all study sites, and written informed consent
was obtained from all parents or guardians before enrolment.
Data
Trial N01263 was an open-label, single-arm, multicentre,
fixed 3-step up-titration study evaluating the pharmacokinet-
ics, safety, and efficacy of brivaracetam in children aged
≥1 month to <16 years. Brivaracetam oral solution was ad-
ministered at weekly increasing doses of approximately
0.4 mg/kg bid, 0.8 mg/kg bid, and 1.6 mg/kg bid for subjects
≥8 years of age and 0.5 mg/kg bid, 1.0 mg/kg bid, and 2.0 mg/
kg bid for subjects <8 years of age. The doses were to be
capped at the adult doses of 25 mg bid, 50 mg bid and
100 mg bid, respectively, for body weight (WT) ≥50 kg.
The study planned to enrol 100 children (≥1 month to
<16 years), recruited in approximately 50 sites, with
localisation-related, generalised or undetermined focal or gener-
alised epileptic syndrome, according to the International League
Against Epilepsy classification. Patients had to be receiving one
to three concomitant AEDs, except levetiracetam which was not
allowed. Hepatic impairment was an exclusion criterion for entry
in the clinical trial. Subjects completed a 1-week prospective
baseline period, followed by a 3-week evaluation period with a
weekly fixed 3-step up-titration based on age. On the last of
7 days of brivaracetam dosing at a scheduled dose level (i.e. at
day 7, day 14, and day 21), two scheduled blood samples were
drawn for plasma determination of brivaracetam and metabolites
in one of three possible time brackets: earlymorning (one sample
before and one between 1 and 2 h post morning dose), late
morning (two samples between 2 and 6 h post morning dose,
at least 2 h apart) or afternoon (two samples between 6 and 12 h
post morning dose, at least 2 h apart), plus one optional blood
sample at a later or intervening time. Only brivaracetam parent
compound data were used for the population pharmacokinetics
modelling. Metabolites data were used for simple estimations of
relative exposures.
Estimated body surface area-normalised glomerular filtra-
tion rate (eGFR) was calculated using the Schwartz bedside
equation [15, 16]. Lean body weight (LBW) was calculated
from total bodyweight and bodymass index (BMI) [17]. Post-
conceptional age (PCA) was only considered relevant for pa-
tients below 3 years; for all other patients, and for patients
where PCA was missing, PCA was calculated as post-natal
age (years) + 0.75. A summary of the population characteris-
tics and main covariates available for inclusion in the analysis
is provided in the online supplementary material as
Supplemental Table 1. The validated bioanalytical method is
also available in the online supplementary material.
Software
The analyses were performed using NONMEM Version 7.2.0
[18] software using the First Order Conditional Estimation
with the interaction option (FOCE-I). 95% confidence inter-
vals (95%CI) were calculated as the estimate ± 1.96 times the
NONMEM-reported standard error for the estimate. An addi-
tional assessment of parameter uncertainty not relying on nor-
mality assumptions was obtained by bootstrapping the final
model 1000 times [19]. Data were further processed using 64
bit R Version 2.15.2 software [20]. Simulations were per-
formed using NONMEM and R. Stepwise covariate model-
ling (SCM, [21]) and bootstrapping was performed using Perl
Speaks NONMEM (PsN) [22] version 3.4.2.
Brivaracetam population pharmacokinetics model
The structural model was a one-compartment model with first
order absorption and elimination together with allometrically
scaled effects of body size on clearance (CL) and volume of
distribution (V). The influence of body size was estimated
using the following equation:
PARi ¼ θ1⋅ COViPOPCOV
 θ2
⋅eηi
where θ1 is the population value of the estimated pharmacokinet-
ic parameter, PARi is the individual-specific parameter value for
the ith subject with the value of the covariate (COVi) scaled to a
population typical value (POPCOV). Both body weight (WT) and
LBWwere assessed as measures of body size. For WT, an adult
population typical value of 70 kg and for LBWa typical value of
50 kg were used for POPCOV to allow easy comparison with
reported adult values. The parameter θ2 is the scaling parameter
for the weight range. If allometric scaling principles are applied,
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θ2 takes on specific (fixed) values for the influence of body size;
these values are 0.75 for CL and 1 for V [23].
Although LBW is not a very convenient measure for dos-
ing adaptations in clinical practice, it was recognised that it
might prove superior in describing the underlying pharmaco-
kinetic properties. However, dosing recommendations were
developed based on simple clinically applicable rules (i.e.
WT-based for specific age ranges).
Exponential models were used to describe the inter-
individual variability (IIV) for the structural model parame-
ters. IIV was calculated as the square root of the diagonal
element in the omega matrix. Proportional and combined ad-
ditive and proportional models were investigated to describe
the residual variability. Proportional error model components
were reported as coefficient of variation (CV).
Comparison between various potentialmodels was based on a
likelihood ratio test using the difference in the NONMEM-
provided Objective Function Value (OFV) for two hierarchical
competing models and where the number of degrees of freedom
is equal to the difference in parameter numbers between the two
models. For structural model updates, the more complex model
was required to be associated with a p value less than 0.01.
The covariates tested in the model for their effects on
brivaracetam clearance were age, PCA, sex, race, ethnicity
(Hispanic/Latino or not), eGFR, carbamazepine co-
administration (CBZ), phenobarbital or primidone co-
administration (PB), valproate co-administration (VPA), inducer
co-administration (presence of CBZ, phenytoin (PHT) or PB),
non-AED CYP3A inhibitor co-administration, and non-AED
CYP2C19 inhibitor co-administration. The effect of PHT was
not assessed since only a single patient had this treatment at entry
in the study. Categorical covariates were investigated in the SCM
approach using a linear model, and continuous covariates as
linear, exponential, and power models [22].
For the forward selection step a p < 0.01 (χ2p=0.01,ν=1 = 6.63)
was used while the backwards deletion step used a p < 0.001
(χ2p=0.001,ν=1 = 10.83).
Body size using LBW was not included in the SCM pro-
cedure but was an a priori part of the structural model, and its
effect on both apparent clearance (CL/F) and apparent volume
(V/F) was incorporated using allometric equations.
Model qualification
Avisual predictive check (VPC) was performed on the final
model parameter estimates to evaluate its predictive perfor-
mance. The VPC looks at the model’s ability to simulate the
same data that have been used for the model development
[24]. Brivaracetam concentrations were simulated 1000
times using the same dose and covariate data and sampling
times from the subjects that were in the data set.
Additionally, model evaluation included the graphical eval-
uation of goodness of fit.
Simulation approaches for paediatric dose adaptations
The obtained covariate model was used to assess whether
dosing strategies for specific paediatric groups were adequate
in producing brivaracetam concentration profiles consistent
with the predicted adult concentration range. The population
estimates from an adult pharmacokinetic model in patients
from phase 3 efficacy trials [25] were used to derive the me-
dian and 90% of the predicted steady state (Css) levels for
adults receiving 100 mg brivaracetam bid (i.e. the highest
recommended dose), irrespective of AED co-administration.
Paediatric simulations using the population estimates from the
final paediatric model were performed with the study admin-
istration schedule (2.0 mg/kg bid for patients <8 years and
1.6 mg/kg bid with a maximum of 100 mg bid for patients
≥8 years). Additional schedules of 2.0 and 2.5 mg/kg bid were
also investigated with a maximum dose of 100 mg bid, inde-
pendent of age.
The developed population model scaled the pharmacoki-
netic parameters using LBW. In order to allow assessment of
dosing-adequacy for WT and age, the NHANES DXA data-
base [26] was used to provide linked demographic variables
(age, WT and LBW) to drive the simulations on 11,087 chil-
dren between 0 and 16 years, with WT ≤100 kg PB, CBZ and
VPA co-administration status was randomly sampled from the
paediatric study dataset. The results of the simulations were
illustrated graphically by superimposing the distribution of
simulated paediatric Css values (median and 90% prediction
interval) on the adult reference range, together with the pre-
dicted Css values for the individual paediatric patients using
the empirical Bayes estimates (EBEs) from the final model.
Metabolites exposures
In order to obtain summary estimates of exposure for the three
metabolites, a basic model with first-order formation rate, sin-
gle compartment distribution, first-order elimination rate and
scaling using LBW was applied to all metabolites separately
to obtain CL estimates. These CL EBEs were used to estimate
steady state concentrations (Css) of each metabolite at the
maximum dose of the applied dosing regimen. Additionally,
Css ratios of the hydroxy metabolite to the parent drug and to
the sum of the four moieties were calculated, in the overall
study population and in the subgroup of patients not taking
inducing AEDs.
Results
A total of 600 BRV plasma concentration-time records were
available in 96 paediatric patients with a well-balanced distri-
bution of patient numbers aged 1 month to <2 years, 2 to
<6 years, 6 to <12 years and 12 to <16 years age groups of
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29, 26, 24 and 17 patients respectively. Brivaracetam pharmaco-
kinetics was adequately described using a one-compartment
model with first-order absorption and allometric scaling of clear-
ance and volume using body size. A combined proportional and
additive residual error model yielded no improvement over a
proportional residual error model. Implementing allometric scal-
ing of brivaracetam clearance and volume resulted in a 204.9
point drop in OFV using theoretical allometric exponents and
lean body weight (p < 0.0001). When WT was used instead of
LBW,OFVincreased by 11.42 points, and therefore the stepwise
covariate searchmodel development continued using LBW. In
the first forward search step, the SCM procedure selected en-
zyme inducer AEDs co-administration as most significant co-
variate. No further covariates were detected, and the backward
search step indicated that the inducer covariate must be
retained in the model.
No effects of categorical covariates race, ethnicity, sex,
CYP3A or CYP2C19 inhibitors were detected and no effects
of age, PCA, or eGFRwere detected using linear, exponential,
or power relationships. This could conclude covariate model
development. However, in the first step, both CBZ, PB, and
VPAwere highly significant covariates and the aggregate ef-
fect of the inducer covariate obscures the individual contribu-
tions. Therefore, individual contributions of these three AED
effects were estimated instead of the inducer covariate to allow
quantification of their respective effects.
All three AEDs had significant effects on CL on their own. In
the combined estimation, co-administration of PB was estimated
to induce a 40.8% increase in clearance, CBZ a 47.9% increase,
and VPA a 10.1% decrease. Even though VPA did not meet the
criteria for inclusion in the model, it was retained nevertheless
since quantification of its contribution was considered informa-
tive. Population parameters for the final model are provided in
Table 1. Shrinkage for bothV/F andKawas substantial (45.6 and
73.4%, resp.) indicating that the information on these parameters
in the current data set is limited, but CL, determining exposure,
was accurately estimated with low shrinkage (6.1%). High
shrinkage in itself is not an issue, but limits diagnostics using
individual empirical Bayes estimates [27].
Goodness of fit plots using conditional weighted residuals
demonstrated the absence of systematic model misspecification
regarding time after dose, and absence of residual effects of WT,
LBW and age (Supplemental Fig. 1). The smooth through the
plot of absolute individual weighted residuals was almost hori-
zontal indicating the applied residual error model was adequate
(Supplemental Fig 2). Finally, goodness of fit plots of
brivaracetam concentrations vs. population predictions and indi-
vidual predictions demonstrated the absence of systematic model
misspecification (Supplemental Fig 3).
Accuracy of final population parameter estimates was
assessed by bootstrapping the paediatric dataset 1000 times
and re-estimating the parameters for these datasets. Twenty-
three non-successful runs were excluded from the calcula-
tions. The results are provided in Table 1 illustrating the close
correspondence between NONMEM estimates and the
bootstrapped result. The only real deviation is seen for the
absorption rate constant (Ka) where the distribution of
bootstrapped estimates is far more skewed than the symmet-
rical distribution assumed in NONMEM.
The VPCs that were performed for the final model were split
by study occasion, age group, and AED co-administration status.
For the overall population, split by study occasion, there was a
close correspondence between 5th, 50th (median), and 95th per-
centiles of the observed data and corresponding simulated
quantiles (see Supplemental Fig. 4). When the data were further
split by age category, the ranges widened due to the reduced
number of observations per category, but observed percentiles
still tended to lie within the simulated areas (Supplemental
Fig. 5). When the dataset was split by AED co-administration,
again observed percentiles fell within the simulated ranges
(Supplemental Fig. 6). These VPCs indicate that the final model
is capable of simulating concentration profiles that correspond to
the original data.
The simulated trial dosing scheme put most of the model-
predicted concentrations (blue area) in the adult range (grey area)
and individual predictions for N01263 paediatric patients (red
dots) were mostly contained within the model-predicted range
(see Fig. 1, top row). However, children aged <1 year and
Table 1 NONMEM parameter
estimates (with 95% confidence
intervals) and bootstrapped
estimates (median and 95% of
estimates) for the final paediatric
brivaracetam model using LBW-
dependent CL and V (normalised
to a 50-kg LBW adult), and
effects of co-administration of
PB, CBZ and VPA
Parameter NONMEM estimates Bootstrapped estimates IIV Shrinkage (%)
CL/F (L/h) 3.63 (3.42/3.85) 3.62 (3.42/3.86) 22.8% 6.1%
V/F (L) 47.8 (43.1/52.5) 47.6 (43.1/51.7) 16.7% 45.6%
Ka (1/h) 1.84 (0.91/2.78) 1.83 (1.26/5.27) 31.9% 73.4%
Allometric scaling CL/F 0.750 fixed
Allometric scaling V/F 1.00 fixed
CL change with PB (%) +40.8 (+19.9/+65.2) +39.8 (+18.3/+65.8)
CL change with CBZ (%) +47.9 (+27.8/+71.2) +48.2 (+26.2/+73.0)
CL change with VPA (%) −10.1 (−18.5/−0.8) −10.0 (−19.5/−0.8)
Residual error (CV, %) 23.4 (19.6/27.1) 23.2 (19.7/26.7) 9.2%
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weighing <10 kg appeared to have a reduced exposure even
though still mostly within the adult range.
By subdividing the simulations by AED co-administration
(background therapy with PB, CBZ, VPA, or excluding these
3 AEDs), it became apparent that the lower plasma concen-
trations in the young age group could be attributed to the more
frequent co-administration of PB (see Fig. 2).
By removing the 20% dose reduction in children aged
≥8 years and simply dosing all patients with 2.0 mg/kg bid
with a maximum of 100 mg bid, the predicted concentration
profile across the paediatric population was still mostly
contained within the adult Css range (Fig. 1, bottom row).
Increasing the dose to 2.5 mg/kg bid across the entire popula-
tion raised the exposure in smaller/younger children closer to
the center of the adult concentration range, but increased the
likelihood of over-dosing in older children, except in the pres-
ence of inducers (Supplemental Fig. 7).
Regarding exposure to the metabolites, the predicted mean
(SD) average plasma concentrations in the group of patients
not taking enzyme inducers and receiving the maximum
scheduled dose (n = 71) were 0.36 (0.15) mg-eq/L, 0.12
(0.05) mg-eq/L, and 0.035 (0.012) mg-eq/L for the hydroxy,
acid, and hydroxyacid derivatives, respectively, compared to
2.10 (0.51) mg/L for brivaracetam. The hydroxy to parent
ratio was 18.4 (10.8)%, while the ratio of hydroxy to total
(sum of all 4 compounds) was 14.1 (6.7)%.
Discussion and conclusions
A population PK model was developed for brivaracetam in
paediatric patients consisting of first-order absorption, single
compartment distribution, and first-order elimination compo-
nents with allometric scaling of CL and V parameters using
fixed theoretical allometric exponents. Lean body weight pro-
vided a slightly better description of CL differences between
patients than WT. Differences between LBW- and WT-based
allometric scaling were small because WT and LBW were
very highly correlated for these paediatric patients.
The paediatric population clearance, 3.63 L/h, (normalised
to a typical adult) was consistent with the population clearance
value of 3.58 L/h found in adults with epilepsy [25] and with
mean values of 3.37 and 3.64 L/h reported in two trials in
healthy adults [13, 27]. Exposures to the three inactive metab-
olites appeared similar to those found in healthy adults, albeit
the hydroxylation ratio was somewhat higher in children with
epilepsy (18 vs 9% [28]), at least partly due to background
therapy with enzyme-inducing AEDs.
Covariate analysis indicated that co-administration with PB,
CBZ or VPAwas associated with a clearance modification: co-
administration with PB, or CBZ was associated with a 29.0 and
32.4% decrease in exposure, respectively. Co-administration
with VPA was associated with an 11.2% increase in exposure.
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Fig. 1 Predicted Css by weight
(left) and age (right) using the
final paediatric population PK
model (red circles: individual
predictions) for children from the
NHANES database using
2 mg/kg bid for patients <8 years,
and 1.6 mg/kg bid for patients
≥8 years with 100 mg bid
maximum dose (top), or 2 mg/kg
bid with 100 mg bid maximum
dose for all patients (bottom). The
blue line is the median simulated
paediatric Css and the blue
shaded area encompasses 90% of
the simulated paediatric patients.
The horizontal grey band
encompasses 90% of the
simulated adult patients receiving
100 mg bid
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received both PB and CBZ, no conclusions are warranted about
the combined effect of CBZ and PB.
No effects on clearance could be attributed to race, ethnic-
ity, sex, co-administration of CYP3A or CYP2C19 inhibitors,
age, PCA or eGFR. The absence of a detectable CYP3A or
CYP2C19 inhibitor effect is no evidence of absence of inter-
action since only two and seven patients were co-administered
with a CYP3A (one each on fluconazole and clarithromycin)
or CYP2C19 (all on omeprazole) inhibitor, respectively. It
should be noted that covariate analysis only detects associa-
tions, and estimated effects should not be confusedwith causal
relationships. The increased exposure observed in the pres-
ence of VPA for instance could be due to confounding with
underlying unknown factors. VPA is a CYP2C9 inhibitor [29,
30] while BRV is not a substrate of this isoenzyme (only one
of its metabolites is, and only partially). In addition, VPA did
not increase BRV concentrations in adults, as evidenced in a
population analysis around 20 times the size of the present
paediatric population [25]. Further, BRV plasma protein bind-
ing is insignificant [11] which rules out the theoretical possi-
bility of a displacement-based interaction [30]. However, a
well-known side effect of chronic VPA is to increase body
weight and fat significantly [31], which could have an influ-
ence on the pharmacokinetics of BRV, being a hydrophilic
compound. Interestingly, levetiracetam exposure appeared
23% higher in a subgroup of adult patients co-administered
with VPA; it was hypothesised that the effect could arise from
the known association between VPA and increased body fat,
since levetiracetam is negligibly metabolised by cytochrome
P450 enzymes [32]. Age-related maturation of metabolism
could not be detected. Increased clearance in young children
could be associated with the more frequent co-administration
of PB as compared to older children.
Simulations demonstrated that the majority of children
reached an exposure similar to adults using the trial dosing
regimen of 2.0 mg/kg bid for patients <8 years and 1.6 mg/kg
bid with a maximum of 100 mg bid for patients ≥8 years,
although smaller children tended to have a slightly reduced
exposure, in the lower end of the adult range, when co-
administered with enzyme-inducing AEDs.
Simulations suggested that a switch to an age-independent
dosing regimen of 2.0 mg/kg bid with a maximum of 100 mg
bid would result in profiles comparable to those attained with
the weight and age-dependent trial dosing regimen.
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Fig. 2 Predicted Css by age split
by co-administration with PB,
CBZ and VPA or absence of PB/
CBZ/VPA using the final
paediatric population PK model
(red circles: individual
predictions) for children from the
NHANES database using
2 mg/kg bid for patients <8 years,
and 1.6 mg/kg bid for patients
≥8 years with 100 mg bid
maximum dose. The blue line is
the median simulated paediatric
Css and the blue shaded area
encompasses 90% of the
simulated paediatric patients. The
horizontal grey band
encompasses 90% of the
simulated adult patients receiving
100 mg bid
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